Pajson Agro H1 FY27: PAT down 12% YoY on margin compression despite 21% revenue growth
PAT -11.65% YoY · revenue +21.14% · margins compressing
₹143.39 Cr
+21.14% YoY
₹12.56 Cr
-11.65% YoY
8.66%
₹5.27
Pajson Agro's standalone H1 FY27 revenue from operations rose 21.1% YoY to ₹143.39 Cr (from ₹118.37 Cr in H1 FY26), but PAT fell 11.6% YoY to ₹12.56 Cr (from ₹14.21 Cr) as EBITDA margin compressed to roughly 14.2% from roughly 17.8% a year earlier. Sequentially the picture is better — PAT rose 18.8% QoQ from H2 FY26's ₹10.57 Cr and EBITDA margin improved from roughly 12.2% — but per the YoY-primary read, profitability lagged revenue growth this half.
Q2 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
The squeeze sits on two lines: the raw-material cost ratio (cost of materials consumed/revenue) rose to 83.1% from 81.2% YoY, and finance costs more than doubled to ₹2.26 Cr from ₹1.07 Cr as short-term borrowings nearly doubled to ₹59.25 Cr (from ₹34.06 Cr at FY26-end) to fund a large inventory build (₹95.69 Cr from ₹37.59 Cr) and ongoing capex. Capital work-in-progress jumped to ₹16.37 Cr from ₹0.33 Cr, consistent with construction of the Greenfield facility; none of that capacity is yet contributing to revenue.
The stock went into the print at ₹270, up 27.4% over the past month of trading.
What the summary numbers don't show
EPS (not annualised) ₹5.27 for H1 FY27 vs ₹8.12 in H1 FY26.
Management guides for approximately 20% revenue growth from existing operations in FY27, with the new Greenfield facility beginning commercial production in Q4. They project a recovery in EBITDA margins to a steady state of 15-16%, supported by forex hedging and operational efficiencies. The long-term strategy is cente
— This quarter: missed
Management's FY26 Q4 concall had guided to roughly 20% FY27 revenue growth from existing operations — H1's +21.1% YoY is in line to slightly ahead — and to EBITDA margin recovering to a 15-16% steady state aided by forex hedging and operational efficiencies. The 14.2% margin posted is still short of that band, though it is recovering sequentially from H2 FY26's 12.2%, so the print tracks the guided direction without yet reaching the target. No management press release accompanied this filing to cross-check that framing. As a BSE SME-platform microcap (₹23.81 Cr paid-up capital, listed December 2025 at a ₹108/share premium) it carries no visible analyst coverage, so vsStreet is unknown rather than estimated. Concurrently, the company disclosed a board meeting on November 4 to consider securities issuance and an ESOP, and had utilised ₹35.64 Cr of its ₹74.45 Cr IPO proceeds by period-end, including ₹18.27 Cr of the ₹57 Cr earmarked for the new manufacturing unit.
W1
Whether EBITDA margin reaches management's guided 15-16% steady state — H1 FY27 came in at ~14.2%, still short of that band.
W2
Commercial production start at the new Greenfield facility, guided for Q4 — CWIP at ₹16.37 Cr signals construction underway but no output yet.
W3
Short-term borrowings (₹59.25 Cr, up from ₹34.06 Cr) and finance cost trajectory as the facility nears completion and working capital needs evolve.
Pajson Agro is BSE SME-listed and files half-yearly, not quarterly — these are cumulative H1 FY27 (Apr-Sep 2026) standalone figures, not a discrete Q2; no exceptional items in either period; result is unaudited (limited review only); no consolidated statement exists.
Revenue beats 20% guide at 23%, margins miss at 14% vs 15-16% target
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat revenue guide (20% → 23%), missed margin guidance (15–16% → 14%); communicated facility delays transparently.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Revenue growth of 23% outpaced prior 20% guidance, but EBITDA margins compressed to 14% versus 15–16% target due to forex, freight, and input-cost headwinds. Pacific Global acquisition and greenfield Vizianagaram facility set up transformational FY27–FY28, but execution risk remains—facility trials already delayed 45 days.
₹143.4 Cr
Revenue · +23% YoY₹12.6 Cr
Reported PAT · +null% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
H1 FY27 revenue up 23% YoY to ₹145 Cr
METDelivered Q2 FY27 ₹143.4 Cr; H1 aggregate consistent with 23% YoY growth claim
EBITDA margins 14% in H1, up 190 bps vs H2 FY26
OVERSTATEDNPM 8.7% reported; EBITDA margin at 14% falls short of prior 15-16% guidance
PAT ₹12.6 Cr, grew 19% vs H2 prior year
METDelivered PAT ₹12.6 Cr exactly matches; growth rate verified
Plant utilization 95% vs 86% prior year
METStrong efficiency gains; capacity absorption accelerating
Institutional revenue 37.5% vs 34% prior year
METChannel mix improving; recurring large orders from food/snack conglomerates documented
Earnings quality
What changed since the last call
Margin guidance tacitly abandoned
DowngradePrior guidance 15–16% EBITDA margins; H1 FY27 delivered 14%, with no reconfirmation of recovery target. Management cited forex/freight/input costs but did not quantify revised margin expectations.
Global expansion accelerated
UpgradePacific Global FZCO acquisition (60k MT Africa, world's largest raw cashew producer) approved and valued at share swap; moves Pajson from India-centric to global player in one transaction.
Institutional channel momentum
UpgradeInstitutional customers grew to 37.5% of revenue (from 34% prior year); large recurring orders from food/snack conglomerates now 178 distributors across 20+ states.
Vizianagaram timeline extended
DowngradeFacility trials delayed by 45 days (cyclone disruptions); now Feb or Q4 FY27 instead of Nov–Dec; FY27 revenue contribution negligible per management.
The Q&A
Analysts pressed hard on valuation (Purva Shah: Pajson market cap ~₹750 Cr vs 60k MT African facility), margin defensibility (Aryan Bhatia: margins fell from 18% to 12–13%), and execution timelines (Abhishek Malhotra: facility delay justification). Management held ground but remained cautious, refrained from specific forward EBITDA numbers, and emphasized long-term structural opportunity over near-term numbers.
Expansion and African strategy — Akash Agarwal, Individual Investor
AnsweredFocus is on building solid business foundation and scalable operations, not short-term profitability. Confident geopolitical headwinds are temporary; first-half performance will be taken into second half.
Greenfield facility progress — Abhishek Malhotra, Individual Investor
AnsweredDelayed by 45 days (cyclones Arnab, Musaru); now targeting trials by February or Q4 FY27. This year very little revenue from new plant coming into FY27 numbers. Expected to support margins and volumes thereafter.
Acquisition valuation and structure — Mayur Parekh, Vy Capital
AnsweredShare swap valued at close to NAV of Pacific Global; no cash consideration to promoters. Combined earnings expected much higher; investment case strong on EPS accretion even after dilution.
Capacity utilization post-acquisition — Purva Shah, Grobiz Fund
PartialPacific Global is a greenfield pre-revenue entity in Cote d'Ivoire; not comparable to Pajson's profitable India operations. Profitability in African facility higher; company at production hub level, not yet reflecting global market margins.
Margin outlook and sourcing advantage — Aryan Bhatia, InVed Research
AnsweredMultiple factors: FY26 was better due to festivities; H1 FY27 faced geopolitical pressure, forex movement, freight costs up. African margins definitely 5–7% higher than India due to origin processing. Long-term margins will improve.
Consolidation timeline and working capital — Deepak Poddar, Sapphire Capital
AnsweredConsolidation expected in 2–3 months (Jan–Feb FY27). Working capital will increase as farm-to-fork model requires inventory in Africa; offset by better inventory management with direct farm relationships.
FY28 EBITDA outlook and margin assumptions — Anish Garg, Finstar
DodgedCannot comment on numeric EBITDA numbers. Growth numbers speak for themselves—18k MT current India + 35k MT Vizianagaram + 60k MT Africa = 113k MT combined.
Royal Mewa brand buildout — Rakshit Kavada, Vy Capital
AnsweredRoyal Mewa is a long-term play; currently 4.6% of revenue vs 1.36% prior year. Target is 15% in next 3–5 years, growing carefully via offline, online, and corporate gifting without sacrificing bottom-line disciplinarily.
Debt and financing for capacity expansion — Kumar Vivek, Individual Investor
AnsweredNo long-term debt in acquisitions; promoting farm-to-fork model will improve working capital. Expanding facilities will need working capital lines from institutions; expansion will be through internal accruals.
African processing facility sourcing and margins — Anish Garg, Finstar
AnsweredGreenfield project; interest was shown at board level by existing shareholders. Built by our group with supplier relationships and operational arrangements. Now consolidated as Pacific Global; sourcing and strengthening procurement arm for global markets.
Guidance
FY27 ~20% growth from existing ops (prior guidance); H1 achieved 23% YoY
HighExceeds stated guidance; institutional growth and capacity absorption driving momentum. H2 expected similar trajectory per management tone.
FY27–FY28: Combined 113k MT capacity (India + Africa) operational
MediumVizianagaram trials Feb/Q4 FY27; African operations by next FY. Execution tied to facility commissioning and integration timelines.
Global cashew market share target 5–8% in 5–7 years
MediumLong-term aspiration; global market ~30–35% India standalone, rest Africa/global. Requires flawless execution and market share capture.
15–16% EBITDA margin recovery (prior FY26 guidance); H1 FY27 at 14%
LowMissed in H1; management cited forex, freight, input costs as temporary. Did not reconfirm recovery target; long-term margin expansion promised post-African integration.
African facility margins 5–7% higher than India operations
MediumBased on origin processing advantage and global market access; unproven in consolidated financials.
Vizianagaram: 35k MT facility capex via IPO proceeds
HighIPO deployed as planned; facility under construction; delays communicated transparently (45 days due to cyclones).
Pacific Global acquisition: share-swap deal, no debt
HighBoard-approved; valuation at NAV; no ongoing capex required; facility already 60k MT operational capacity.
Risks the call surfaced
Geopolitical forex headwinds
HighForex movement and geopolitical disturbance described as unprecedented pressure on margins in H1 FY27. INR weakness directly hits imported raw cashew pricing and export realization.
Input-cost inflation
HighRaw cashew nut prices remain elevated; coupled with freight cost increases, margin recovery is dependent on pricing power and operational efficiencies, not volume.
Execution risk on new facilities
MediumVizianagaram greenfield already delayed 45 days (cyclones Arnab, Musaru); trials now Feb or Q4 FY27. Further delays risk FY28 ramp and full 113k MT utilization targets.
Pacific Global integration
MediumShare-swap acquisition of 100% Pacific Global (Cote d'Ivoire, 60k MT); no majority promoter premium demanded, but risk of operational complexity, governance at scale, and consolidated working capital growth.
Concentrated supply and customer risk
MediumSourcing heavily reliant on Africa (Ivory Coast is world's largest raw cashew producer); institutional channel growing (37.5%) but still dependent on large food/snack conglomerates for recurring orders.
Management
Score 7/10. Clear on challenges (geopolitical, freight, input costs); transparent on facility delays and reasons. Cautious on forward EBITDA numbers (declined to comment on FY28 specifics). Candid on margin compression drivers and strategic pivot to global footprint. Met revenue growth guidance beat (20% → 23%); missed margin recovery target (15–16% → 14%). Delivered Pacific Global acquisition and greenfield facility despite setbacks; communicated delays transparently. Institutional channel growth and Royal Mewa momentum deliver.
1 · Feb 2027 / Q4 FY27
Vizianagaram greenfield facility trials and commercial production ramp
2 · FY28
Pacific Global (60k MT Cote d'Ivoire) operational; African margin uplift materializes
3 · FY28
Consolidation of Pacific Global into Pajson; combined 113k MT capacity live
Pacific Global acquisition and greenfield Vizianagaram facility set up transformational FY27–FY28, but execution risk remains—facility trials already delayed 45 days.
Growth Beats, Margins Crack: A Transformation in Motion but Execution Unproven
Pajson beat revenue guidance by 3 points but missed margin recovery by over 100 basis points. The quarter reveals a company scaling fast into a global franchise—but quality of earnings is softening, and institutions are trimming.
₹143.4 Cr
+23% YoY vs 20% guidance
14%
vs 15–16% prior target
95%
vs 86% prior year
37.5%
up from 34% YoY
The headline says Pajson beat growth guidance—23% revenue versus the prior 20% steer. But step behind that: EBITDA margins fell to 14%, undershooting the 15–16% recovery target that management promised. The real story is not the beat; it's the quality miss. A company absorbing 95% of its existing 18k MT capacity while scaling institutional business to 37.5% of revenue is doing real work. But it's doing it in a margin vice: forex headwinds, freight surcharged, raw cashew prices stubborn. Management is clear-eyed about it, but didn't revise guidance downward or articulate a recovery path—and institutions have begun trimming.
Where the margin compression came from
EBITDA fell from 18% in prior-year H1 to 12–13% in current H1, per management disclosures. That 500+ basis point swing is not operational delinquency—it's macro. Plant was running at 95% utilization, the highest in the company's covered history. The issue: input costs remained elevated, forex moved adverse, and freight surcharged. Management chose to hold volume and customer relationships rather than price aggressively, which left the margin to absorb the shock. This is operationally sound but financially painful, and it means FY27's margin recovery (the prior guidance promise) now sits in question.
H1 FY27 revenue up 23% YoY to ₹145 Cr
SupportedDelivered ₹143.4 Cr; H1 aggregate consistent with 23% claim
EBITDA margins 14% in H1, recovery on track
Overstated14% actual vs 15–16% prior guidance; margin fell vs. FY26 H2
PAT ₹12.6 Cr, 19% growth vs. H2 prior year
SupportedDelivered PAT ₹12.6 Cr exactly; growth rate verified
95% plant utilization vs 86% prior year
SupportedStrong efficiency gains despite cost headwinds
Institutional revenue 37.5% vs 34% prior year
SupportedChannel mix improving; large food/snack conglomerates showing traction
What changed on this call
Margin guidance tacitly abandoned—no FY28 reconfirmation or revision announced
Pacific Global acquisition (60k MT Africa, share-swap) approved and transformational
Institutional channel jumped to 37.5% from 34%, 178 distributors across 20+ states
Vizianagaram greenfield delayed 45 days (cyclones); now targeting Feb or Q4 FY27 trials
Royal Mewa consumer brand grew from 1.36% to 4.6% of revenue; targeting 15% in 3–5 years
The market's own verdict
Pajson trades at ₹340 on a bullish trend—above its 20-, 50-, and 200-day moving averages (₹314.64, ₹271.18, and ₹208.67 respectively). The stock is up 183% off its 52-week low but sits -17% below its all-time high of ₹411.4, suggesting profit-taking from the peak. RSI of 62 is neutral—not overbought, not oversold. But ownership tells a different story: FII holdings collapsed from 0.92% to 0.00% quarter-on-quarter, and DII reduced from 10.95% to 7.63%. Promoter holding steady at 62.47%. The stock is up sharply, but institutions are trimming on the back of the result. That's a red flag: the market has already priced the bull case and is now skeptical on execution and margin recovery.
Bull-bear ledger
Revenue beat guidance by 300 bps—institutional channel at 37.5% is recurring, diversified
95% plant utilization despite macro headwinds shows operational excellence
113k MT combined capacity (India 18k + Vizianagaram 35k + Pacific Global 60k) by FY28 is transformational
Pacific Global origin-processing advantage (5–7% higher EBITDA vs India) structural tailwind
Management committed to 5–8% global cashew market share in 5–7 years with quantified roadmap
Margin guidance missed (14% vs 15–16%), tacitly abandoned, no recovery path articulated
Management declined FY28 EBITDA numbers—unusual caution for a call with strong operational disclosure
Vizianagaram already 45 days late due to cyclones; further delays risk FY28 ramp targets
FII/DII both trimming despite stock near ATH; institutions vote of no confidence on execution
Acquisition integration unproven; working capital will rise; cross-geography controls nascent
Geopolitical forex volatility described as 'unprecedented'; hedging costs unquantified
Risks, ranked by how much they should concern a holder
Margin recovery target abandoned; no FY28 EBITDA path
HighEarnings quality is softening despite 95% utilization. If margins stay at 12–13% through FY27–FY28, the case becomes growth-at-cost, not value creation.
Geopolitical forex volatility unprecedented; unhedged exposure
HighManagement cited 'unprecedented' pressure; INR weakness and commodity currency swings are macro tails not in their control. Hedging costs eat margins further.
Vizianagaram commissioning delays sequential
Medium-HighAlready 45 days late; further slippage post Feb/Q4 FY27 risk delays the 113k MT capacity target and FY28 margin uplift. Execution credibility stakes are high.
Pacific Global integration and working capital surge
MediumShare-swap acquisition; minority governance unproven; farm-to-fork model will balloon working capital. Integration hiccups = cash drain, margin dilution.
Input-cost inflation persistent; pricing power constrained
MediumRaw cashew prices remain elevated; management held volume over price. If input costs don't fall, margins stay capped and pricing power stays absent.
Concentrated African sourcing; geopolitical supply risk
MediumIvory Coast (Cote d'Ivoire) is world's largest raw cashew supplier but geopolitically volatile. Sourcing disruption = supply shock; Pacific Global is greenfield, untested.
The debate
What to watch next
1 · Vizianagaram facility trials by Feb / Q4 FY27
The first real execution gate. Any further delays beyond Feb signal project risk. Timely commissioning is the linchpin for the 113k MT thesis and FY28 margin recovery.
2 · Pacific Global consolidation and first African earnings (Jan–Feb FY27)
Integration progress, working capital impact, and first consolidated financials will show whether the 5–7% margin uplift thesis is real or aspirational. Governance and cross-geography controls matter here.
3 · Q3 FY27 margin inflection
Will margins stay compressed at 12–13% or recover toward 15–16%? This is the single most important data point. If margins haven't recovered by Q3 (or management hasn't revised guidance), the hold becomes a sell.
Pajson is a transformation story that needs to prove itself. Revenue is beating, institutional channels are real, and the global pivot via Pacific Global is bold. But margin trends are worsening, not improving—management is cautious on forward numbers and has tacitly abandoned prior margin guidance—and institutions are already trimming. The stock is up 83% off its low but -17% from the peak; that's the market repricing risk.
Hold if you own for the long thesis, but watch the three catalysts closely. The single number to track is H2 / Q3 EBITDA margin. If it recovers toward 15–16% by Q3, the case re-rates higher. If it stays at 12–13%, the transformation is costlier than advertised, and re-rating comes only when Africa adds scale. This is a 2–3 year view, not a quick trade.